Mäenpää J, Holli K, Pasanen T
Departments of Obstetrics and Gynecology, and Oncology and Radiotherapy, University Hospital, PO Box 2000, FIN-33521, Tampere, Finland.
Eur J Cancer. 2000 Sep;36 Suppl 4:S61-2. doi: 10.1016/s0959-8049(00)00229-x.
Toremifene is a chlorinated triphenylethylene that is indicated for postmenopausal breast cancer. For advanced disease, toremifene has been found to be as effective and at least as well tolerated as tamoxifen. The same appears to apply for adjuvant setting. After a total cumulative clinical exposure to toremifene of approximately 140000 patient-years, only 9 cases of endometrial carcinoma have been reported. The annual hazard rate (per 1000 patient-years) of developing endometrial carcinoma in breast cancer patients on adjuvant toremifene is 1.14 (versus tamoxifen 2.0 and placebo 0.4). Although toremifene (being a partial agonist) may unmask pre-existing endometrial tumours, there is no clinical data implying that it would per se cause endometrial carcinoma.
托瑞米芬是一种氯化三苯乙烯，适用于绝经后乳腺癌。对于晚期疾病，已发现托瑞米芬与他莫昔芬疗效相同且耐受性至少一样好。这似乎同样适用于辅助治疗。在托瑞米芬的累计临床总暴露量约为140000患者年之后，仅报告了9例子宫内膜癌病例。接受辅助性托瑞米芬治疗的乳腺癌患者发生子宫内膜癌的年风险率（每1000患者年）为1.14（他莫昔芬为2.0，安慰剂为0.4）。虽然托瑞米芬（作为部分激动剂）可能会使已有的子宫内膜肿瘤显现出来，但没有临床数据表明它本身会导致子宫内膜癌。
